List of Excipients in Branded Drug FABHALTA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	FABHALTA	iptacopan	0078-1189	AMMONIA	2041-05-25
Novartis Pharmaceuticals Corporation	FABHALTA	iptacopan	0078-1189	FERRIC OXIDE RED	2041-05-25
Novartis Pharmaceuticals Corporation	FABHALTA	iptacopan	0078-1189	FERRIC OXIDE YELLOW	2041-05-25
Novartis Pharmaceuticals Corporation	FABHALTA	iptacopan	0078-1189	FERROSOFERRIC OXIDE	2041-05-25
Novartis Pharmaceuticals Corporation	FABHALTA	iptacopan	0078-1189	GELATIN	2041-05-25

FABHALTA Excipient Strategy and Commercial Opportunities for Iptacopan

Last updated: September 3, 2026

FABHALTA (iptacopan) uses a conventional immediate-release hard-capsule platform with widely available excipients. The commercial opportunity is therefore less likely to come from a novel excipient patent and more likely to arise from supply security, capsule optimization, global formulation adaptation, manufacturing efficiency, and differentiated follow-on dosage forms. FABHALTA has substantial commercial value because iptacopan is approved for paroxysmal nocturnal hemoglobinuria (PNH) and primary IgA nephropathy (IgAN), with additional complement-mediated disease opportunities under development.

What excipients are used in FABHALTA capsules?

FABHALTA is a 200 mg immediate-release hard capsule administered twice daily. The U.S. prescribing information identifies the following inactive ingredients:

Formulation component	Reported excipient or material	Functional role
Capsule fill	Lactose monohydrate	Diluent and bulk carrier
Capsule fill	Microcrystalline cellulose	Diluent, compression and flow aid
Capsule fill	Croscarmellose sodium	Disintegrant
Capsule fill	Colloidal silicon dioxide	Glidant and moisture-flow aid
Capsule fill	Magnesium stearate	Lubricant
Capsule shell	Gelatin	Structural capsule shell
Capsule shell	Titanium dioxide and colorants	Opacity and product identification

The formulation is consistent with a standard oral solid dosage form rather than a lipid-based, amorphous solid dispersion, modified-release, or biologic delivery system. FDA identifies FABHALTA as an immediate-release capsule containing 200 mg of iptacopan hydrochloride monohydrate equivalent to 200 mg of iptacopan. The label permits administration with or without food, which reduces food-effect complexity in commercial use (FDA, 2023).

What does the excipient composition indicate about formulation risk?

The principal technical risks are likely to involve:

1. Content uniformity at a relatively high drug load.
2. Powder flow and segregation during capsule filling.
3. Moisture control for the active ingredient and excipient blend.
4. Dissolution consistency across manufacturing sites.
5. Gelatin-shell stability and colorant compatibility.
6. Global compliance for lactose, titanium dioxide, and animal-derived gelatin.

The use of lactose, microcrystalline cellulose, croscarmellose sodium, silicon dioxide, and magnesium stearate creates a broad supplier base. That lowers substitution risk for individual materials but increases the importance of process control. A competitor can often reproduce a conventional capsule architecture without copying the exact excipient ratios, provided the finished product meets pharmaceutical equivalence and quality requirements.

What are the largest commercial opportunities for FABHALTA excipient suppliers?

The highest-value opportunities are in qualified supply, second-source development, capsule technology, and lifecycle reformulation.

1. Dual sourcing and supply assurance

Novartis has a commercial incentive to qualify more than one supplier for each high-volume excipient and capsule component. The most practical opportunities are:

• Pharmaceutical-grade lactose monohydrate.
• Low-moisture microcrystalline cellulose.
• Consistent-particle-size croscarmellose sodium.
• High-purity colloidal silicon dioxide.
• Magnesium stearate with controlled specific surface area.
• Pharmaceutical gelatin shells.
• Printed, colored, and opacity-controlled capsule shells.

For FABHALTA, an excipient supplier that can provide global regulatory packages, change-control discipline, elemental impurity data, nitrosamine risk assessments, and multi-region manufacturing capacity has a stronger position than a supplier competing only on price.

2. Excipient grades that improve capsule-filling performance

The commercial formulation appears suitable for direct blending and capsule filling. Suppliers can create value by offering grades designed for:

• Improved flow at high drug loading.
• Lower segregation during transfer.
• Reduced electrostatic charging.
• Lower lubricant sensitivity.
• More consistent disintegration across humidity conditions.
• Reduced fill-weight variation.

A co-processed diluent-disintegrant system could be commercially attractive if it preserves dissolution and content uniformity while reducing the number of formulation inputs. Such a system would require comparative development work and regulatory support because replacing separate excipients may alter the critical quality attributes of the finished capsule.

3. Capsule-shell and printing systems

The capsule shell is a visible commercial identifier and a potential source of supply and manufacturing differentiation. Opportunities include:

• Halal- or vegetarian-compatible capsule systems.
• Non-gelatin capsule shells for selected markets.
• Lower titanium dioxide or titanium-dioxide-free opacity systems.
• Improved moisture-barrier capsule materials.
• High-resolution anti-counterfeit printing.
• Capsule-shell systems optimized for automated blister packaging.

A shell change would require comparability testing and, depending on the nature of the change, regulatory reporting. It could be valuable if Novartis seeks a global formulation that avoids regional restrictions on colorants, titanium dioxide, or animal-derived gelatin.

What formulation patents could protect FABHALTA?

The core commercial protection for FABHALTA is expected to center on iptacopan composition-of-matter, therapeutic use, and related pharmaceutical patents rather than the basic use of common excipients.

Potential formulation claim categories include:

Claim category	Commercial relevance
Iptacopan chemical compound	Protects the active ingredient
Salt, polymorph, or crystalline form	Can restrict alternative active-material forms
Immediate-release capsule composition	May cover selected excipient ranges or performance parameters
Manufacturing process	Can protect blending, granulation, filling, or crystallization steps
Treatment of PNH	Supports indication-specific protection
Treatment of IgA nephropathy	Supports later-label commercial protection
Complement-mediated diseases	May extend use protection into new markets

Common excipients such as lactose, cellulose, croscarmellose sodium, and magnesium stearate are unlikely to provide meaningful standalone exclusivity. A formulation patent would need to claim a specific combination, ratio, particle-size distribution, dissolution profile, stability result, or manufacturing process. Suppliers can still obtain commercial leverage through proprietary grades, know-how, regulatory files, and quality agreements even when the excipient itself is not patent-protected.

When does FABHALTA lose regulatory exclusivity?

FABHALTA received its initial U.S. approval in December 2023 for PNH. Iptacopan was a new molecular entity, making five-year NCE exclusivity the principal Hatch-Waxman barrier to an ANDA filing based on the reference product, subject to the statutory rules governing Paragraph IV challenges. The effective NCE period is expected to run into late 2028, while a Paragraph IV filing could generally be submitted during the fourth year of the NCE period, subject to the applicable statutory framework (FDA, 2023; U.S. Congress, 1984).

PNH is a rare disease, and FABHALTA may also benefit from orphan-drug exclusivity for the approved PNH indication. Orphan exclusivity operates separately from NCE exclusivity and can restrict approval of the same drug for the same disease or condition during the orphan period. The practical scope depends on the FDA orphan designation and the competing product's indication.

The later IgAN approval expands the addressable market but does not restart the original five-year NCE exclusivity period. It can, however, support additional method-of-use patents, labeling restrictions, and indication-specific litigation.

What is the Orange Book status of FABHALTA?

FABHALTA is an FDA-approved small-molecule drug and is eligible for Orange Book listing of applicable patents. The relevant NDA is NDA 218276. Orange Book-listed patents can create ANDA certification obligations and provide a basis for Paragraph IV litigation.

The likely patent challenge points are:

• Core iptacopan patents.
• Salt or solid-form patents.
• Pharmaceutical composition patents.
• Treatment-method patents.
• Manufacturing patents where the ANDA applicant relies on a patented process or formulation.

An excipient supplier usually has limited direct Orange Book exposure because excipients are not independently listed as protected active ingredients. Risk increases when a supplier provides a proprietary co-processed excipient or a capsule technology that is expressly incorporated into a listed formulation patent.

Which companies are challenging FABHALTA?

Publicly visible competitive pressure currently comes primarily from approved complement inhibitors and emerging therapies, not from biosimilars.

PNH competition

FABHALTA competes with:

• Ultomiris (ravulizumab), AstraZeneca.
• Soliris (eculizumab), AstraZeneca.
• Empaveli (pegcetacoplan), Apellis Pharmaceuticals.
• Established transfusion-support and immunosuppressive approaches in selected patients.

FABHALTA differentiates itself as an oral proximal complement factor B inhibitor. Its twice-daily oral dosing can appeal to patients who prefer to avoid intravenous or subcutaneous administration, although adherence and infection-risk management remain commercial considerations.

IgA nephropathy competition

In IgAN, FABHALTA competes with targeted-release budesonide products, endothelin-pathway therapies, renin-angiotensin system treatment, sodium-glucose cotransporter-2 inhibitors used within nephrology practice, and other complement-directed programs. The commercial contest depends on proteinuria reduction, preservation of kidney function, safety, dosing convenience, reimbursement, and the strength of confirmatory outcomes data.

How strong is the patent estate for FABHALTA?

The estate is commercially meaningful because iptacopan is a novel small molecule with multiple disease applications. Novartis has publicly described patent protection extending into the 2030s, with company materials identifying protection through at least 2035 in major markets. Exact expiry dates vary by patent family, jurisdiction, patent-term adjustment, supplementary protection certificate, pediatric extension, and the scope of each claim (Novartis, 2024).

Patent strength is highest for:

• The active molecule and related chemical forms.
• Treatment of complement-mediated disease.
• Specific approved and pipeline indications.
• Solid-state and manufacturing technologies.

Patent strength is generally lower for:

• Standard excipient combinations.
• Conventional hard-capsule architecture.
• Commodity excipient grades.
• Routine capsule-filling processes without a demonstrated technical effect.

What generic entry risks exist for FABHALTA?

The main generic-entry scenario is a conventional ANDA containing iptacopan in an equivalent immediate-release capsule. The principal barriers are:

Risk area	Effect on generic entry
NCE exclusivity	Delays ANDA approval and limits early filing
Orange Book patents	Creates certification and litigation risk
Solid-form patents	May force development of a non-infringing form
Method-of-use patents	Can limit labeling for protected indications
Clinical safety monitoring	Adds pharmacovigilance and risk-management obligations
Manufacturing complexity	Creates quality and scale-up risk
Market access	Requires payer coverage and specialist adoption

A first Paragraph IV filer could receive 180-day generic exclusivity if statutory conditions are met, but the value of that position would depend on patent litigation, settlement terms, pediatric extensions, and whether multiple filers submit challenges.

What manufacturing and geographic IP barriers affect FABHALTA?

Commercial manufacture is likely to require control of:

• Iptacopan solid form and particle properties.
• Blend uniformity.
• Capsule fill-weight precision.
• Dissolution and disintegration.
• Moisture exposure.
• Packaging protection.
• Analytical methods for assay, impurities, and degradation products.

Geographic barriers are more likely to arise from patent-family differences and regulatory requirements than from excipient availability. The European Union, United States, Japan, China, and other markets may have different rules for titanium dioxide, colorants, gelatin origin, excipient monographs, and change-control reporting.

A supplier that can provide equivalent pharmaceutical grades across ICH and non-ICH markets can reduce the need for regional formulation changes. That has value for Novartis because every formulation variation can create additional stability, bioequivalence, filing, and supply-chain work.

What licensing deals and settlement agreements affect FABHALTA?

The principal commercial rights holder is Novartis. FABHALTA originated from the company’s complement-development portfolio and is commercialized by Novartis. Publicly reported licensing arrangements involving commodity excipients are not a central part of the product's value chain.

Potential future licensing activity is more likely in:

• Regional commercialization.
• Complement-targeted combinations.
• New indications such as C3 glomerulopathy.
• Pediatric or liquid dosage forms.
• Proprietary capsule or excipient technology.
• Manufacturing partnerships.

No broad public settlement structure should be assumed for generic iptacopan until a Paragraph IV case is filed and resolved. Settlement economics would depend on the challenged patent claims, launch date, strength of the invalidity case, and any authorized-generic arrangement.

What excipient strategies could extend FABHALTA’s commercial lifecycle?

The most credible lifecycle strategies are:

1. A lower-burden once-daily formulation, if pharmacokinetically and clinically feasible.
2. A pediatric-friendly sprinkle capsule or oral suspension.
3. A capsule with improved humidity protection.
4. A tablet or capsule platform with lower manufacturing cost.
5. A formulation adapted for patients with lactose intolerance or regional excipient restrictions.
6. A fixed-dose combination with another complement or kidney-protective therapy.
7. A formulation optimized for combination use in IgAN.
8. A multiparticulate dosage form that improves dose flexibility.

Each strategy must preserve exposure, food-effect performance, and clinical safety. For a highly potent small molecule, reducing dose frequency could have greater commercial value than adding a complex delivery system.

What is the revenue exposure and competitive opportunity?

FABHALTA has two important commercial engines:

Market	Commercial driver	Excipient implication
PNH	Oral alternative to infusion and injection therapies	Reliable high-volume capsule supply and patient-friendly packaging
IgAN	Larger nephrology population and chronic use	Cost-efficient scale-up, adherence-oriented packaging, and lifecycle formulations

PNH provides a specialist launch base, while IgAN offers a substantially broader chronic-disease opportunity if confirmatory efficacy and reimbursement support continued use. The commercial value of excipient innovation will therefore depend on whether it lowers cost, improves adherence, enables new age groups, or supports a differentiated label.

Key Takeaways

• FABHALTA uses a conventional immediate-release hard capsule with lactose, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, gelatin, titanium dioxide, and colorants.
• Commodity excipients are unlikely to create strong standalone patent protection.
• The most attractive supplier opportunities are dual sourcing, global regulatory support, capsule-shell innovation, and improved powder-flow grades.
• FABHALTA’s main exclusivity barriers are NCE exclusivity, potential orphan exclusivity for PNH, Orange Book patents, and later method-of-use protection.
• Biosimilar risk is not relevant because iptacopan is a small molecule. Generic ANDA risk is the relevant challenge.
• The largest lifecycle opportunities are once-daily dosing, pediatric delivery, regional excipient adaptation, and formulations supporting chronic IgAN treatment.
• Patent protection is publicly described as extending into the 2030s, with company materials identifying protection through at least 2035 in major markets.

FAQs

Can a generic manufacturer use the same excipients as FABHALTA?

Yes. Common excipients are generally available for use by an ANDA applicant, provided the finished product meets pharmaceutical equivalence, bioequivalence, quality, and labeling requirements and does not infringe a valid formulation or process patent.

Is FABHALTA suitable for a lactose-free reformulation?

Potentially. Replacing lactose with another diluent could address regional labeling preferences or patient tolerability concerns, but the reformulation would require comparative dissolution, stability, manufacturing, and regulatory assessment.

Could a co-processed excipient create a competitive advantage for FABHALTA?

Yes. A co-processed diluent-disintegrant or flow-enhancing system could reduce manufacturing variability and simplify supply. Its commercial value would depend on demonstrated performance and whether the formulation creates patentable technical effects.

Does the IgAN approval create a new patent expiry date?

No. A supplemental indication does not restart iptacopan’s original NCE exclusivity period. It can create separate method-of-use and indication-specific protection.

Is a biosimilar pathway available for iptacopan?

No. Iptacopan is a chemically synthesized small molecule. Competitors would generally pursue the ANDA generic-drug pathway rather than the FDA biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2023). FABHALTA (iptacopan) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). FDA approves first oral targeted treatment for paroxysmal nocturnal hemoglobinuria. FDA.

3. U.S. Food and Drug Administration. (2024). FABHALTA (iptacopan) approval materials for primary IgA nephropathy. FDA.

4. Novartis. (2024). Annual report 2024. Novartis AG.

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.